I note that Jefferies isn’t one of the 12 analysts listed.
And while there are 20 covering analyst firms listed on Acadia’s website, Jefferies isn’t one of them.
But I believe it once did provide coverge.
On March 13 2023 (just after DayBue approval) a Jefferies analyst put a Sell on ACAD, with a $15 price target.
Previously, on 17 June 2022, Jefferies upgraded ACAD from Neutral to Buy, with a Price Target of $25, but then downgraded to Underperform with a Price Target of just $10 on 21 June, 2022, after a negative FDA drug advisory committee outcome for Nuplazid.
Jefferies commenced coverage of Neuren in June 2022.
Acadia, page-93
-
- There are more pages in this discussion • 516 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.91 |
Change
-0.030(0.15%) |
Mkt cap ! $2.544B | |||
| Open | High | Low | Value | Volume |
| $19.95 | $20.00 | $19.50 | $8.294M | 417.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 443 | $19.87 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.91 | 917 | 2 |
View Market Depth
| Last trade - 16.10pm 20/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |